M
Michelle J Cole
Researcher at Public Health England
Publications - 115
Citations - 4185
Michelle J Cole is an academic researcher from Public Health England. The author has contributed to research in topics: Neisseria gonorrhoeae & Antibiotic resistance. The author has an hindex of 32, co-authored 100 publications receiving 2904 citations. Previous affiliations of Michelle J Cole include European Centre for Disease Prevention and Control & Health Protection Agency.
Papers
More filters
Journal ArticleDOI
Sustained transmission of high-level azithromycin-resistant Neisseria gonorrhoeae in England: an observational study.
Helen Fifer,Michelle J Cole,Gwenda Hughes,Simon Padfield,Christa Smolarchuk,Neil Woodford,Adrian Wensley,Nazim Mustafa,Ulf Schaefer,Richard M. Myers,Kate Templeton,Jill Shepherd,Anthony Underwood +12 more
TL;DR: HL-AziR could emerge in isolates with low azithromycin MICs and eliminate the effectiveness of azithroitcin as part of dual therapy for the treatment of gonorrhoea, according to this observational study.
Journal ArticleDOI
Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020
Victoria Hall,Victoria Hall,Sarah Foulkes,Andre Charlett,Ana Atti,Edward J.M. Monk,Ruth Simmons,Edgar Wellington,Michelle J Cole,Ayoub Saei,Blanche Oguti,Katie Munro,Sarah Wallace,Peter Kirwan,Madhumita Shrotri,Amoolya Vusirikala,Sakib Rokadiya,Meaghan Kall,Maria Zambon,Mary Ramsay,Tim Brooks,Colin S Brown,Meera Chand,Susan Hopkins,Susan Hopkins +24 more
TL;DR: A prior history of SARS-CoV-2 infection was associated with an 83% lower risk of infection, with median protective effect observed five months following primary infection, which is the minimum likely effect as seroconversions were not included.
Journal ArticleDOI
Overall Low Extended-Spectrum Cephalosporin Resistance but high Azithromycin Resistance in Neisseria gonorrhoeae in 24 European Countries, 2015.
Michelle J Cole,Gianfranco Spiteri,Susanne Jacobsson,Neil Woodford,Francesco Tripodo,Andrew J Amato-Gauci,Magnus Unemo +6 more
TL;DR: The 2015 Euro-GASP sentinel system revealed high, but stable azithromycin resistance and low overall resistance to ceftriaxone and cefixime, which may be attributable to the effectiveness of the currently recommended first-line dual antimicrobial therapy.
Journal ArticleDOI
WGS analysis and molecular resistance mechanisms of azithromycin-resistant (MIC >2 mg/L) Neisseria gonorrhoeae isolates in Europe from 2009 to 2014
Susanne Jacobsson,Daniel Golparian,Michelle J Cole,Gianfranco Spiteri,Irene Martin,Thea Bergheim,Maria José Borrego,Brendan Crowley,Tania Crucitti,Alje P. van Dam,Steen Hoffmann,Samo Jeverica,Peter Kohl,Beata Młynarczyk-Bonikowska,Gatis Pakarna,Angelika Stary,Paola Stefanelli,Peter Pavlik,Eva Tzelepi,Raquel Abad,Simon R. Harris,Magnus Unemo +21 more
TL;DR: The main azithromycin resistance mechanisms were the A2059G mutation (high-level resistance) and the C2611T mutation (low- and moderate- level resistance) in the 23S rRNA gene.
Journal ArticleDOI
Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial
Jonathan D C Ross,Clare Brittain,Michelle J Cole,Claire Dewsnap,J. Harding,Trish Hepburn,Louise E. Jackson,Matthew Keogh,Tessa Lawrence,Alan A Montgomery,Tracy E Roberts,Kirsty Sprange,Wei Tan,Sukhwinder Thandi,John White,Janet Wilson,Lelia Duley +16 more
TL;DR: G-ToG did not find that a single dose of gentamicin 240 mg was non-inferior to a single doses of ceftriaxone 500 mg for the treatment of gonorrhoea, when both drugs were combined with a 1 g dose of oral azithromycin.